Obexelimab

DB15032InvestigationalProtein Based Therapies

Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus).

Mechanism: Pharmacologically active on Low affinity immunoglobulin gamma Fc region receptor II-b and B-lymphocyte antigen CD19
Curator reviewed
Also known as: AMG 729 · humanized anti-CD19, Fc engineered, monoclonal antibody with enhanced binding to FcyRIIb · Immunoglobulin G1, anti-(human CD19 antigen) (human-mus musculus monoclonal XMAB5871 heavy chain), disulfide with human-mus musculus monoclonal XMAB5871 light chain, dimer · XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Code names: XMAB5871

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Obexelimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.